Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice

Gandiga, Prateek C.; Zhang, J; Sangani, Sapna; Thomas, Phillip; Werth, Victoria P.; George, Michael

doi:10.1111/bjd.18133

Cited by 9 publications

(10 citation statements)

References 8 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Commercial assays to detect MSAAs are now in widespread use worldwide. Limited validation, particularly for rarer autoantibodies, has been a growing concern among the myositis community [ 6 , 12 , 13 ]. Previous studies in this area have been small, with low numbers of sera containing individual MSAA specificities [ 6 , 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity

Tansley

Betteridge

et al. 2020

Rheumatology

View full text Add to dashboard Cite

Objectives In order to address the reliability of commercial assays to identify myositis-specific and -associated autoantibodies, we aimed to compare the results of two commercial immunoassays with the results obtained by protein immunoprecipitation. Methods Autoantibody status was determined using radio-labelled protein immunoprecipitation for patients referred to our laboratory for myositis autoantibody characterization. For each autoantibody of interest, the sera from 25 different patients were analysed by line blot (Euroline Myositis Antigen Profile 4, EuroImmun, Lübeck, Germany) and dot blot (D-Tek BlueDiver, Diagnostic Technology, Belrose, NSW, Australia). Sera from 134 adult healthy controls were analysed. Results Overall commercial assays performed reasonably well, with high agreement (Cohen’s κ >0.8). Notable exceptions were the detection of rarer anti-synthetases with κ < 0.2 and detection of anti-TIF1γ, where κ was 0.70 for the line blot and 0.31 for dot blot. Further analysis suggested that the proportion of patients with anti-TIF1γ may recognize a conformational epitope, limiting the ability of blotting-based assays that utilize denatured antigen to detect this clinically important autoantibody. A false-positive result occurred in 13.7% of samples analysed by line blot and 12.1% analysed by dot blot. Conclusion The assays analysed do not perform well for all myositis-specific and -associated autoantibodies and overall false positives are relatively common. It is crucial that clinicians are aware of the limitations of the methods used by their local laboratory. Results must be interpreted within the clinical context and immunoprecipitation should still be considered in selected cases, such as apparently autoantibody-negative patients where anti-synthetase syndrome is suspected.

show abstract

Section: Discussionmentioning

confidence: 99%

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity

Tansley

Betteridge

et al. 2020

Rheumatology

View full text Add to dashboard Cite

show abstract

“…There is however, a need for better standardization of measurement of DM autoantibodies. A recent study showed just 14% of patients with DM had MSAs and 21% had MSAs when testing was done in commercial labs [170] . Hopefully the detection rate of autoantibodies will improve with time and allow better correlation with disease phenotype.…”

Section: Dm Rashes and The Antisynthetase Syndromementioning

confidence: 99%

239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018

Mammen¹,

Allenbach

Stenzel

et al. 2020

Neuromuscular Disorders

165

113

View full text Add to dashboard Cite

“…Statements released by the Association of Professors of Dermatology (APD) in April and June 2020 addressed student concerns and suggested modifications to the application process (Table I). 1,2 To complement these statements, the Dermatology Interest Group Association (DIGA) hosted a webinar for dermatology residency hopefuls. Similar webinars have been held by national specialty organizations in orthopedic surgery, ophthalmology, and emergency medicine.…”

Section: A National Webinar For Dermatology Applicants During the Covmentioning

confidence: 99%

“…To the Editor: Laboratory panels for myositis-specific antibodies (MSA) and myositis-associated antibodies (MAA) are increasingly being used in the diagnosis and prognostication of dermatomyositis (DM). 1,2 However, many commercial panels used in clinical settings have limited validation compared to other methodologies. 3 To understand the accuracy of commercial myositis panels in the clinical setting, we performed a cross-sectional analysis of patients with DM, comparing commercially available myositis panels to panels performed in the research setting.…”

mentioning

confidence: 99%

Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective

Ravishankar

Concha

Yan

et al. 2021

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Utilization patterns and performance of commercial myositis autoantibody panels in routine clinical practice

Cited by 9 publications

References 8 publications

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity

239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018

Accuracy of commercial panels to evaluate myositis autoantibodies: A single-institution perspective

Contact Info

Product

Resources

About